Merck: applies to FDA for molnupiravir (Covid)
(CercleFinance.com) - Merck and Ridgeback Biotherapeutics today announced that Merck has submitted an emergency use clearance application to the US Food and Drug Administration (FDA) for molnupiravir, a experimental oral antiviral drug, for the treatment of mild-to-moderate Covid in adults at risk of developing severe forms.
The interim analysis from a phase III study showed that molnupiravir reduced the risk of hospitalization or death by approximately 50% after 29 days.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
The interim analysis from a phase III study showed that molnupiravir reduced the risk of hospitalization or death by approximately 50% after 29 days.
Copyright (c) 2021 CercleFinance.com. All rights reserved.